Trials / Recruiting
RecruitingNCT06153251
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 187 (estimated)
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986453 | Specified dose on specified days |
| DRUG | Fludarabine | Specified dose on specified days |
| DRUG | Cyclophosphamide | Specified dose on specified days |
Timeline
- Start date
- 2024-01-23
- Primary completion
- 2030-05-02
- Completion
- 2030-05-02
- First posted
- 2023-12-01
- Last updated
- 2026-03-18
Locations
19 sites across 4 countries: United States, France, Germany, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06153251. Inclusion in this directory is not an endorsement.